Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo by Jason J. Zoeller, Roderick T. Bronson, Laura M. Selfors, Gordon B. Mills, Joan S. Brugge

Get full text

Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy. by Jason J Zoeller, Michael F Press, Laura M Selfors, Judy Dering, Dennis J Slamon, Sara A Hurvitz, Joan S Brugge

Get full text

Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer by Jason J. Zoeller, Aleksandr Vagodny, Veerle W. Daniels, Krishan Taneja, Benjamin Y. Tan, Yoko S. DeRose, Maihi Fujita, Alana L. Welm, Anthony Letai, Joel D. Leverson, Vincent Blot, Roderick T. Bronson, Deborah A. Dillon, Joan S. Brugge

Get full text

STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer by Qiwei Wang, Johann S. Bergholz, Liya Ding, Ziying Lin, Sheheryar K. Kabraji, Melissa E. Hughes, Xiadi He, Shaozhen Xie, Tao Jiang, Weihua Wang, Jason J. Zoeller, Hye-Jung Kim, Thomas M. Roberts, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Deborah A. Dillon, Eric P. Winer, Nancy U. Lin, Jean J. Zhao

Get full text

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07) by Sara A. Hurvitz, Jennifer L. Caswell-Jin, Katherine L. McNamara, Jason J. Zoeller, Gregory R. Bean, Robert Dichmann, Alejandra Perez, Ravindranath Patel, Lee Zehngebot, Heather Allen, Linda Bosserman, Brian DiCarlo, April Kennedy, Armando Giuliano, Carmen Calfa, David Molthrop, Aruna Mani, Hsiao-Wang Chen, Judy Dering, Brad Adams, Eran Kotler, Michael F. Press, Joan S. Brugge, Christina Curtis, Dennis J. Slamon

Get full text